CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.Company Information
- Company Name
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- CIK
- CIK0001100682
- Category
- Large accelerated filer
- Ticker: Exchange
- CRL: NYSE
- Fiscal Year End
- December 27
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8731
- SIC Description
- Services-Commercial Physical & Biological Research
- Ticker
- CRL
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-03
- Last sale
- 2026-08-25
- Shares purchased (TTM)
- 25
- Shares sold (TTM)
- 165,990
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 54,156,861
- Shares outstanding
- 48,021,000
- Ownership
- 112.78%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 11.81%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 192 | 192 | 214 | 207 | 183 | 229 | 195 | 210 | 179 | 327 | 277 | 157 | ||||||
| Accounts Receivable Net Current | 712 | 700 | 709 | 734 | 768 | 757 | 721 | 754 | 762 | 787 | 780 | 799 | ||||||
| Inventory Net | 346 | 360 | 299 | 303 | 280 | 290 | 279 | 336 | 349 | 361 | 380 | 293 | ||||||
| Prepaid Expense Current | 100 | 102 | 96 | 122 | 110 | 130 | 103 | 93 | 98 | 94 | 88 | 102 | ||||||
| Prepaid Expense And Other Assets Current | 179 | 135 | 129 | 166 | 130 | 100 | 106 | 102 | 111 | 99 | 83 | 93 | ||||||
| Assets Current | 1,529 | 1,489 | 1,447 | 1,532 | 1,470 | 1,506 | 1,403 | 1,495 | 1,499 | 1,668 | 1,609 | 1,444 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1,495 | 1,510 | 1,655 | 1,592 | 1,607 | 1,587 | 1,604 | 1,640 | 1,614 | 1,619 | 1,640 | 1,525 | ||||||
| Equity Method Investments | 206 | 210 | 207 | 195 | 216 | 214 | 218 | 236 | 232 | 244 | 244 | 302 | ||||||
| Operating Lease Right Of Use Asset | 330 | 318 | 361 | 374 | 386 | 403 | 412 | 385 | 386 | 384 | 394 | 375 | ||||||
| Goodwill | 3,077 | 3,040 | 2,764 | 2,922 | 2,936 | 2,873 | 2,847 | 3,125 | 3,080 | 3,070 | 3,095 | 2,885 | ||||||
| Finite Lived Intangible Assets Net | 253 | 249 | 340 | 571 | 602 | 656 | 723 | 778 | 800 | 828 | 864 | 886 | ||||||
| Deferred Income Tax Assets Net | 54 | 89 | 67 | 37 | 47 | 49 | 42 | 38 | 36 | 37 | 40 | 34 | ||||||
| Other Assets Noncurrent | 588 | 826 | 293 | 291 | 296 | 294 | 278 | 307 | 301 | 303 | 309 | 155 | ||||||
| Assets | 7,532 | 7,730 | 7,135 | 7,514 | 7,561 | 7,582 | 7,528 | 8,004 | 7,948 | 8,153 | 8,195 | 7,607 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 141 | 134 | 149 | 170 | 146 | 149 | 140 | 136 | 133 | 130 | 169 | 136 | ||||||
| Employee Related Liabilities Current | 188 | 167 | 269 | 270 | 228 | 197 | 179 | 211 | 177 | 190 | 213 | 224 | ||||||
| Contract With Customer Liability Current | 203 | 194 | 210 | 238 | 268 | 250 | 248 | 252 | 247 | 256 | 242 | 250 | ||||||
| Accrued Liabilities Current | 380 | 372 | 270 | 229 | 232 | 242 | 232 | 208 | 192 | 191 | 228 | 198 | ||||||
| Other Liabilities Current | 223 | 226 | 222 | 216 | 207 | 211 | 194 | 205 | 198 | 188 | 203 | 185 | ||||||
| Liabilities Current | 1,135 | 1,094 | 1,120 | 1,122 | 1,080 | 1,051 | 994 | 1,012 | 948 | 955 | 1,055 | 994 | ||||||
| Long Term Debt And Capital Lease Obligations | 2,620 | 2,663 | 2,136 | 2,185 | 2,332 | 2,511 | 2,240 | 2,327 | 2,409 | 2,660 | 2,647 | 2,514 | ||||||
| Operating Lease Liability Noncurrent | 408 | 393 | 434 | 443 | 454 | 475 | 484 | 433 | 429 | 418 | 419 | 390 | ||||||
| Deferred Income Tax Liabilities Net | 79 | 81 | 95 | 123 | 109 | 107 | 107 | 168 | 165 | 180 | 191 | 185 | ||||||
| Other Liabilities Noncurrent | 403 | 511 | 138 | 189 | 185 | 196 | 195 | 237 | 225 | 235 | 223 | 173 | ||||||
| Liabilities | 4,644 | 4,742 | 3,924 | 4,063 | 4,161 | 4,341 | 4,020 | 4,176 | 4,175 | 4,449 | 4,536 | 4,256 | ||||||
| Redeemable Noncontrolling Interest Equity Carrying Amount | 43 | 42 | 41 | 40 | 40 | 42 | 41 | 41 | 46 | 58 | 57 | 40 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 1,986 | 1,967 | 1,947 | 2,016 | 1,993 | 1,978 | 1,966 | 1,971 | 1,957 | 1,939 | 1,906 | 1,877 | ||||||
| Retained Earnings Accumulated Deficit | 1,372 | 1,374 | 1,389 | 1,944 | 1,890 | 1,838 | 1,812 | 2,123 | 2,054 | 1,960 | 1,887 | 1,720 | ||||||
| Treasury Stock Value | - | - | - | - | - | - | - | - | - | - | - | -24 | ||||||
| Treasury Stock Common Value | -323 | -210 | 0 | -363 | -363 | -357 | 0 | -120 | -18 | -9 | 0 | - | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -196 | -191 | -172 | -192 | -166 | -265 | -317 | -193 | -270 | -250 | -196 | -268 | ||||||
| Stockholders Equity | 2,846 | 2,941 | 3,165 | 3,405 | 3,353 | 3,194 | 3,467 | 3,787 | 3,727 | 3,646 | 3,597 | 3,306 | ||||||
| Minority Interest | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 5 | 4 | 6 | 5 | 5 | ||||||
| Liabilities And Stockholders Equity | 7,532 | 7,730 | 7,135 | 7,514 | 7,561 | 7,582 | 7,528 | 8,004 | 7,948 | 8,153 | 8,195 | 7,607 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 9 | 8 | 10 | 14 | 13 | 16 | 18 | 24 | 25 | 25 | 26 | 21 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | ||||||
| Common Stock Shares Issued | 50 | 49 | 49 | 51 | 51 | 51 | 51 | 52 | 52 | 52 | 51 | 51 | ||||||
| Shares Outstanding | 48 | 48 | 49 | 49 | 49 | 49 | 51 | 51 | 52 | 52 | 51 | 51 | ||||||
| Treasury Stock Common Shares | 2 | 1 | 0 | 2 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) — SEC Financial Statements & Analysis
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is a services-commercial physical & biological research company. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. trades on NYSE as: CRL. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. carries a market cap of $10.89B, a P/E ratio of -46.17x, a P/B ratio of 3.83x, a P/S ratio of 2.72x, an enterprise value of $13.27B, and an EV/EBITDA multiple of 30.07x. On profitability, it posts a gross margin of 42.15%, an operating margin of 2.25%, a net margin of -5.90%, a Return on Equity (ROE) of -7.61%, a Return on Assets (ROA) of -3.13%, and a Return on Invested Capital (ROIC) of 1.66%. Per share, it reports EPS of $-4.91, diluted EPS of $-4.91, free cash flow per share of $7.72, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -0.74% year-over-year, net income growth of 285.28% year-over-year, and EPS growth of 294.33% year-over-year. On the balance sheet, it maintains a current ratio of 1.35x, a quick ratio of 0.95x, working capital of $394.36M, a debt-to-equity ratio of 1.63x, a debt ratio of 0.62, an interest coverage ratio of 0.85x, free cash flow of $370.61M (TTM), and net debt of $2.38B. Figures sourced from SEC EDGAR.
- Market Cap
- $10.89B
- P/E TTM
- -46.17x
- EPS TTM
- $-4.91
- P/B TTM
- 3.83x
- ROE TTM
- -7.61%
- ROA TTM
- -3.13%
- Debt To Equity
- 1.63x
- Free Cash Flow TTM
- $370.61M
- Net Revenue TTM Growth 1Y
- -0.74%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. in?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) operates in the Services-Commercial Physical & Biological Research industry.
What exchange does CRL trade on?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) trades on the NYSE.
When was CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s most recent SEC filing?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is CRL's market cap?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a market capitalization of $10.89B as of 2026-06-30.
What is CRL's EPS (earnings per share)?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s trailing twelve month EPS is $-4.91 as of 2026-06-30.
What is CRL's ROE (return on equity)?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s trailing twelve month Return on Equity (ROE) is -7.61% as of 2026-06-30.
What is CRL's ROA (return on assets)?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s trailing twelve month Return on Assets (ROA) is -3.13% as of 2026-06-30.
What is CRL's ROIC (return on invested capital)?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s trailing twelve month Return on Invested Capital (ROIC) is 1.66% as of 2026-06-30.
What is CRL's EV/EBITDA?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)'s trailing twelve month EV/EBITDA is 30.07x as of 2026-06-30.